Our pan-cancer analysis revealed that the expression of HAR1A was downregulated in a broad spectrum of cancers, including lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), uterine corpus endometrial carcinoma (CESC), liver hepatocellular carcinoma (LIHC), prostate adenocarcinoma (PRAD), and stomach adenocarcinoma (STAD) [9]. Here, HAR1A is linked to bladder transitional cell carcinoma.